gene therapi pure potenti
top perform smid cap biotech
combin de-risk asset high option initi coverag
gene therapi pure-play uniqur outperform rate tp see qure
hemophilia high probabl asset huntington
diseas hd provid among highest option coverag univers
platform elev ceil essenti free preclin gene therapi call option
hem fabri addit mirna/cns-direct program
de-risk correspond platform valid support
floor valu led near-norm factor ix level mean week
bleed event patient treat dose-confirm studi despit
small sampl size result suggest function cure pfe
similar timelin model captur hemophilia gene
therapi market pend final commerci strategi po adjust
contribut npv
trial carri high risk signific potenti preclin
result gene therapi highli encourag drug produc
meaning reduct mutant normal mhtt/wthtt protein function benefit
seen across multipl hd anim model signific risk remain ahead dose
first clinic patient end requir deep brain
administr risk around degre drug dispers brain safe limit
reduc wthtt estim preval hd opportun annual
incid revenu support dcf-deriv tp
adjust base po add
valuat risk target price base dcf project
use discount rate catalyst includ data
initi updat possibl late
risk thesi includ clinic regulatori commercial/competit
valuat metric
number share
 close
legal entiti disclosur statu non-u analyst us disclosur credit suiss seek busi
compani cover research report result investor awar firm may conflict interest could
affect object report investor consid report singl factor make invest decis
profit tax
chang work capit
flow oper
free cash-flow firm
flow invest
chang net cash/debt
total liabil equiti
share wtd average
price book
roe stated-return
qure biotechnolog compani focus develop gene therapi
treatment genet devast diseas
blue sky scenario reflect posit earli result
result increas probabl success
correspond increas platform valu
grey sky scenario reflect failur reduct
correspond platform/pipelin valu
 close
initi coverag uniqur outperform rate target price qure
gene therapi pure-play multipl develop program built-out manufactur
capabl posit stock partial clinic de-risk
develop hemophilia huntington diseas high
risk/reward opportun blockbust potenti earlier stage gene therapi program
hemophilia fabri etc add long-term option well
huntington diseas devast neurolog disord character progress loss
motor control cognit function ultim result death diseas caus
mutat huntingtin gene htt result product mutant huntingtin
protein toxic neuron symptomat patient
anoth patient diseas yet develop symptom
gene therapi encod microrna design reduc mutant
wild-typ huntingtin protein therapi carri ad risk given novel mechanist
approach awar one somewhat similar gene therapi knockdown approach
clinic benitec biopharma shrna hepat fact also reduc normal
huntingtin protein preclin result encourag led meaning
reduct mhtt protein across hd anim model improv motor control increas
surviv addit therapi safe anim model across speci
clinic trial expect start dose patient immin earli result potenti next year
hem wholly-own asset promis clinic data like provid floor
valu qure see program worth fulli de-risk produc
near-norm factor ix level mean week bleed event patient
treat dose-confirm studi small sampl size short durat follow-up
limit data date result suggest function cure hemophilia
trial on-going result expect
target price deriv use blend valuat base dcf
 dcf use discount rate in-lin late-stag develop
compani assign po success expect
revenu base preval patient use hd gene therapi long-term
qure captur market assum price gross separ assign
po expect gener sale assum
captur hemophilia gene therapi market price estim
gross risk failur due safeti concern lack efficaci failur
trial regulatori set-back commerci risk financ risk
credit suiss biotech short-term qure outlook expect investor focus
earli clinic progress huntington diseas think disclosur compani
begun dose patient confirm major earli safeti issu
occur support stock appreci
credit suiss biotech long-term qure outlook expect stock true
updat roche/ioniss wave life scienc initi data hd antisens
oligonucleotid aso program may impact investor view likelihood success
hd gene therapi potenti commerci opportun
credit suiss biotech qure outlook longer term see qure possibl
emerg attract target within coverag univers shorter term deal
seem less like consid recent capit rais
found safe anim model speci
therapi result dose-depend reduct mutant htt mhtt
mrna protein level striatum human
mous mutant huntingtin lower also observ minipig model
lentiviru rat model mutant huntingtin lower result
function surviv benefit mous dose
figur gene therapi approach vastli attract
serial intrathec aso inject qure abil target exon lack
passeng strang could posit differenti therapi vs
knock mutant normal huntingtin htt
significantli reduc level normal huntingtin may creat clinic
advers outcom complet lack normal htt embryon
lethal mice separ elimin htt adult mice may caus
calcif thalamu region brain roche/ioniss aso
hd program result transient increas neurofila light chain
nfl biomark may associ brain damag
transient increas nfl may procedur relat also
possibl increas nfl relat reduct normal htt
may impact express gene anim model may
use predict safeti therapi
construct program acknowledg signific risk stage develop target root caus
diseas mutant huntingtin protein therapi result encourag safeti efficaci across anim model given advanc gene
therapi administr deep brain gener expect drug deliv right part brain reduc mhtt remain
uncertain earli cours diseas intervent need stage diseas may greatli influenc degre respons therapi
make efficaci assess comparison program challeng safeti product human like biggest unknown
off-target effect risk excess lower normal huntingtin uncertain distribut huntingtin lower therapi found
safe anim model across speci howev unclear much result extrapol human instanc
microrna construct target normal non-human primat htt therefor difficult assess risk side-effect associ excess
becom standard care hd
patient symptom anoth diseas
yet develop symptom given case famili patient
gener well diagnos gener sale
potenti competitor may limit market opportun includ
wave ionis/roch voyag patient may uncomfort
irrevers gene therapi instead favor aso
wave ionis/roch approach
huntington diseas hd common monogen neurolog disord avail disease-modifi treatment make
among largest potenti gene therapi indic develop success expect command sale
depend overal product profil drug
develop opportun
demonstr compel product profil patient
achiev function cure week follow-up
nathwani hem trial decad ago suggest hemophilia gene
therapi provid multi-year durabl efficaci nathwani trial
observ year count trial like
success drug differenti less stringent
screen requir becom standard care hemophilia
clinic data patient efficaci may
repeat larger sampl safeti issu may emerg
patient dose commerci qure may struggl vs
/onc hemophilia gene therapi significantli
resourc alreadi formulari presenc establish
hemophilia space drug benefix
construct trial success data patient hemophilia gene therapi
trial evidenc safeti efficaci use padua variant expect multi-year durabl support
pfe/onc program data nathwani studi assign market qure pend result program
dose confirm studi initi resultsroch acquir hemophilia report lt follow-up data huntington diseas initi dose studyl hemophilia submit initi result coupl top-lin hemophilia earli resultsl charl martineau pm univers toronto novemb
gene therapi huntington
hd devast condit high unmet need signific pharma/biotech
interest current two aso approach clinic test least two
gene therapi expect enter clinic soon
shown lower mhtt protein speci provid function
benefit mice think number unknown relat strategi target broad
reduct htt protein make high risk/veri high reward develop effort
 much normal htt protein safe reduc much mhtt
need reduc hd patient consist across variou
investig new drug applic ind approv earli
clinic result demonstr mhtt reduct expect initi
favor efficaci signal even patient could creat consider
immedi valu hd opportun qure gene therapi platform
broadli believ earli posit data could add much
symptomat huntington diseas patient unit state
incid patient annual believ total address market
opportun gene therapi could compar duchenn muscular
dystrophi dmd ww preval incid repres one
lucr gene therapi market opportun
huntington diseas hd common monogen neurolog disord
develop world symptomat men women unit state
bate et al diseas character widespread neuron degrad lead
loss motor control cognit function patient gener diagnos
mild incoordin slight involuntari movement time patient develop
sever chorea involuntari bodi movement begin lose independ
requir assist eat dress gradual loss cognit capabl late
stage diseas chorea may begin subsid patient often non-verb
bedridden disease-modifi therapi manag diseas
palli natur patient typic die year diseas onset often due
complic immobl aspir pneumonia infect
diseas gener caus autosomal-domin inherit trinucleotid repeat
expans huntingtin gene patient one mutat huntingtin gene one
toxic neuron hd lead widespread brain atrophi neuron striatum
one first region affect lead sever chorea associ diseas
diagnosi diseas fairli straightforward base clinic featur famili histori
genet confirm review famili histori import case
occur patient famili histori diseas advent genet test clinician
abl diagnos patient suspect hd prior onset symptom
peopl trinucleotid repeat expect develop diseas even
symptomat today bate et al clinician indic diseas gener well
diagnos among patient symptomat howev presymptomat patient
well diagnos individu choos undergo genet test
despit famili histori diseas given bleak prognosi lack meaning
pauciti treatment option lack tri
mani compani sought develop therapi treatment huntington diseas
though succeed period end may overal success rate
compound develop travessa et al attribut low histor
success rate combin factor includ
repres specif aspect huntington diseas symptomolog
phenotyp vari across model howev believ scientif commun
made signific advanc recent year develop better mous
model two larg anim model diseas hd minipig sheep
model miniarikova et al relat gene therapi treatment modal
multipl anim need use understand drug impact aspect
previou experiment base less clear biolog
less sophist mechan action previou agent often test
therapeut hypothes consid tenuou
pfizer/mediv dimebon seek improv mitochondri function
hd patient advanc understand genet improv
understand antisens oligonucleotid mirna allow therapi
develop target root caus diseas aggreg mutant
huntingtin mhtt protein respons caus widespread neuron death
clinic expert spoken believ new genetic-bas huntington
therapi much higher probabl success clinic
qure develop gene therapi treatment hd patient therapi
util capsid deliv gene encod silenc microrna mirna
prevent product huntingtin protein htt microrna leverag endogen
gene-silenc machineri call risc rna-induc silenc complex innat human
bind huntingtin gene transcript thu prevent translat protein figur
detail
figur mechan action
qure demonstr safeti efficaci therapi across anim model
speci see figur detail variou model includ
transgen mous therapi result dose-depend reduct
mutant htt mrna protein level striatum figur accord
qure explor higher dose model understand safeti efficaci
achiev sustain total htt lower striatum
cortex result cognit improv prevent striatal volum
transgen mous hd mice statist signific rotarod
improv surviv benefit surviv benefit dose
gc see figur figur compani measur htt lower
model report dose administr method
compar use mous model model
suggest function improv observ start mhtt lower
lentivir hd rat therapi result reduct htt mrna
dose gc addit therapi induc overt immun respons
construct gener passeng strand vivo
transgen huntington diseas minipig hd minipig dose
led signific reduct human mhtt median
striatum median frontal cortex month administr
non-human primat therapi evidenc broad tissu distribut
vg per dna rang gc dose throughout
putamen caudat thalamu cortex qure abl assess
immunogen profil drug nhp abl assess effect total
huntingtin lower model construct target nhp huntingtin
figur preclin model use uniqur program
speciesspecif modelanim model pathologygener detail anim transgen inclus month motor cognit psychiatr disturbancesfull-length transgen human mous model cross modelsth mice two copi mutant human htt gene murin htt express shown mhtt fragment gener intracellular cleavag differ subcellular localis truncat mhtt warbi et al mousesever phenotyp format htt aggreg rapidli progress motor cognit deficit prematur deathmost commonli use htt mous modelrandom insert human mutant htt exon mous genomesomat instabl manifest variabl length report limit cross trial comparisonsratlentivir hd rat modelrat develop rapid local neuropatholog includ htt aggregationrat behavior deficitsmodel creat inject rat lentiviru carri mutant htt allel specif mutat htt perfect match select construct minipighd minipig tghd minipig show mutant htt accumulationther recent evid anim develop symptomsknockin hd minipig insert fragment mutant httnon-human primaten/ahealthi animalshealthi charl martineau pm univers toronto novemb
figur mutant htt protein lower striatum
figur mutant htt protein lower month hd
figur therapi also led surviv benefit hd
aav distribut may determin clinic
clinic qure plan bilater inject therapi striatum specif
putamen caudat structur locat deep within brain huntington diseas
global brain diseas medium spini neuron msn striatum among first
region affect diseas initi loss msn lead classic hd
hyperkinet phenotyp chorea isnt later diseas evid
widespread neuron death across cortex observ figur detail
figur striatum region affect earlier cours hd
howev widespread drug distribut like essenti maxim therapeut benefit
primari determin vector spread choic capsid deliveri vehicl
uniqur use associ potenti broad distribut
brain markaki et al burger et al differenti wide use
capsid associ minim spread throughout brain qure
non-human primat studi found dose vg/ml contain gfp
fluoresc protein use evalu gene therapi distribut control
promot promot use qure led widespread neuron
latter point note grow bodi literatur support need target
astrocyt addit neuron american societi gene cell therapi
confer research sanofi report mutant huntingtin protein astrocyt alon
neuron lead cognit issu stanek et al
qure incorpor two featur associ administr aid
mri-guid imag imag help ensur proper region
treat instanc uniqur hd minipig studi htt lower
seen cortex dose gc/anim clinic expert spoken
believ clinic meaning although caveat best
guess exact amount mhtt lower need human clinic benefit
hd yet elucid howev differ transduct observ
later hemispher brain author conclud
result use mri imag miniarikova et al subsequ nhp
convection-enhanc deliveri convection-enhanc deliveri ced techniqu
gener pressur gradient tip infus cathet deliv
therapeut directli interstiti space central nervou system studi
found pressur infus aav serotyp ced yield much
widespread distribut brain simpl inject bobo et al
continu see question respect degre vector distribut follow
deep brain inject abil achiev meaning htt protein reduct distal tissu
specif extent confid extrapol preclin result clinic
set unknown point unlik healthi non-human primat potenti even
non-symptomat hd minipig huntington diseas patient may widespread
corticostriat degener diseas advanc preferenti make use
anterograd transport nucleu axon high enough concentr via
retrograd transport axon nucleu transport mechan reli
connect putamen motor cortex could compromis hd
patient suggest stage diseas may also influenc therapeut effect
believ vector distribut unknown hd patient could issu may
potenti mediat base thought deliber dose strategi escal plan
know preclin model demonstr dose-depend htt lower surmis
larg dose may provid enhanc distribut brain
safeti consider gene therapi target
view safeti major point risk enter clinic note extrem
signific high unmet need novel hd therapi potenti dramat benefit
gene therapi reason think mani risk may
manag even manifest degre
procedur risk therapi inject deep brain requir
needl travers larg section brain reach intend target
striatum qure preclin studi minipig die result combin
thalamu putamen dose approach addit infus process take time
open brain potenti pathogen risk infus flow
quick bubbl could form potenti advers implic
ultim believ safeti risk associ procedur mitig
compani sinc modifi dose protocol target striatum
putamen caudat nucleu indic thalamu may difficult
tissu target primari tissu affect huntington diseas
qure also incorpor mri-guid deliveri ensur right tissu
target monitor much structur fill addit gene
therapi parkinson diseas previous deliv striatum
minim safeti concern voyag axov clinic program clinician
also reflect us risk worth potenti benefit hd
patient popul sinc clinic deterior certain death altern
risk off-target effect therapi reli nucleotid guid strand
locat subsequ silenc huntingtin mrna risk
genes/mrna could similar nucleotid sequenc could silenc
therapi potenti lead advers consequ qure report
miqur technolog residu passeng strand lower risk
off-target effect figur detail addit therapi
off-target effect preclin studi figur detail
compani
therapi appear
outcompete/oversatur risc machineri alter natur gene silenc
process recal microrna small regulatori rna express anim
plant affect translat stabil target messeng rna mrna
product taken rna-induc silenc complex risc complex
use mirna sequenc guid risc appropri place
messeng rna point bind mrna either cut mrna
prevent translat case huntingtin protein
figur miqur passeng strand reduc risk
figur analysi ip deriv neuron astrocyt find sign
off-target effect
unknown safeti risk associ lower normal huntingtin protein
htt perhap largest unknown degre normal huntingtin protein
lower safe uniqur therapi broadli reduc mutant wild-typ
huntingtin protein hd autosomal-domin diseas one allel produc
mutant htt protein allel produc normal htt protein
complet elimin wild-typ normal htt embryon lethal mice
may neg impact adult neuron function lead potenti calcif
preclin model hd minipig mice model use
understand potenti detriment impact broadli lower human htt
protein anim also produc anim htt mirna
construct target human htt protein murin minipig htt
protein may still produc mous huntingtin similar human huntingtin
qure abl address question preclin data
safe dose mous model believ support
concept safe lower wild-typ htt mous model rel
new importantli mice two copi mutant human htt
gene background murin htt express obscur safeti find
compani believ function benefit could result huntingtin lower
explor high dose model understand safeti compani
find detriment effect result htt lower striatum
month mous model
addit believ fact microrna spread throughout brain via
extracellular vesicl may mitig risk program properti
allow broad htt lower throughout brain potenti allow
even distribut throughout brain without excess reduct site infus
ionis-httrx offer comp frame earli
key rational optim qure program support appar earli clinic
progress seen ionis/roch hd antisens oligonucleotid program ionis-httrx similar
qure gene therapi approach ionis/roch drug work reduc number
mrna transcript therebi reduc amount total huntingtin protein mhtt
wild-typ htt trial random placebo ascend dose
rang administ everi week compani also explor everi
dose ole treatment ionis-httrx dose via intrathec inject led
reduct mhtt csf month ioniss preclin model
suggest csf reduct translat reduct mhtt cortex
reduct mhtt caudat
earli signal function improv design show
signific improv efficaci measur howev degre mhtt
lower correl improv score three month sever function
rho cuhdr primari endpoint support ex-u
approv therapi primari endpoint base upon
roch discuss regul caution howev clear
dose respons observ although may function small number
seriou advers event date patient discontinu trial
tabrizi et al observ consid mild unrel
treatment particularli signific qure ionis/roch
approach reduc mutant wild-typ huntingtin protein level recal
diseas autosom domin
said dose- time-depend increas csf ventricular volum
increas observ neurofila light chain discuss
detail figur detail result
ionis/roch therapi develop trial recent expand
roch dose drug either everi two everi four month recent
commentari roch continu suggest optim program figur
figur roch continu strong confid hd asset although recent commentari sound cautiou
figur ionis/roch trial design baselin result
ionis/roch result gener encourag increas csf level tau
marker brain inflamm neurofila light chain nfl protein observ rais
question investor clinic expert
nfl protein releas acut chronic neuron damag one studi
nfl predict subsequ occipit gray matter atrophi widespread white matter reduct
johnson et al rise nfl level dose- time-depend manner may
indic httrx treatment could increas neuron damag clinician spoken
specul find could potenti result damag spinal
column/ventricl due procedur excess fluid volum deliveri could
indic exacerb diseas process
ole trial roche/ioni explor dose less frequent dose
show less impact nfl level interestingli nfl level spike month
slowli move back toward baselin treatment continu figur detail
ioni anoth aso spinraza approv treatment spinal muscular atrophi
sma spinraza known lower nfl level patient sma spinraza dose
volum huntington diseas aso dose
total volum unclear
meanwhil tau patholog found post-mortem brain sampl hd patient
coloc mhtt addit studi found signific correl tau mhtt
csf clinic measur diseas progress niemel et al wild et al
sex race cognit assess function capac score motor mutant htt csf chang csf mhtt mean sd lower mhttcsf mhtt chang lower mhttcsf nfl chang want see increasecsf tau chang want see increaseventricular volum chang want see increasewhol brain volum chang want see decreasecaud volum chang want see decreasefunct stabil increas cuhdr scoreuhdr score associ higher function percent chang pre-dos day last avail post-dos timepoint latter day day charl martineau pm univers toronto novemb
figur httrx dose associ less impact nfl level
initi data expect
ind clear first patient trial expect
compani report follow
relat studi
detail
dose cohort total patient expect compani wait
day dose first patient cohort dose cohort
recent reveal gc low-dos cohort gc high-dos cohort
consist compani publish dose translat work compani
estim human vg/brain dose expect lead mhtt
lower striatum/cortex vg/brain dose
expect lower mhtt striatum/cortex figur
trial design
multicent random control double-blind primari safeti
endpoint evalu follow-up period patient control
group receiv imit surgeri control patient may elig receiv
complet studi oner protocol consid
high unmet need motiv hd patient popul expect trial
design limit enrol furthermor placebo-control double-blind natur
studi allow greater extrapol result move ahead
enrol early-stag patient repeat earlier patient
treat better potenti outcom sinc neuron die cant recov
limit patient repeat ensur patient rapid
expect declin includ studi length greatest predictor
age diseas onset natur histori diseas bate et al
base ioni experi believ efficaci signal could emerg within month
treatment efficaci endpoint includ clinic paramet uhdr quantit
motor function volumetr mri mr biomark mhtt level csf
efficaci measuer collect period total month studi period
accord expert evid follow would clinic meaning support
therapi potenti activ
cuhdr expert indic slow rate declin cuhdr
would clinic meaning patient diseas stage see annual
declin point therefor clinician look see per
year slow diseas schobel et al expert expect may take
year see clear evid slow diseas progress scale
mhtt chang diseas modif anim model hd occur
mhtt lower cortex requir valid via function benefit
mri/mr chang specif huntingtin protein chang measur csf
brain human studi csf level appear time lower
cortex level roch aso qure caution csf mhtt chang
ideal biomark csf level close align cortic mhtt
protein level oppos mhtt protein level deep brain addit exon
fragment secret csf fragment particularli toxic
total function capac scale score rang
higher score higher function sensit earli
chang disabl divid five stage stage
repres score stage ii score stage score
stage iv score stage score across patient rate
function declin patient first year follow diagnosi see
averag declin per year marder et al presum
acceler higher repeat patient doctor
spoken mention slow rate declin would clinic
meaning although could take year becom appar
mri/mr chang advanc mri allow identif patholog
chang vivo particularli loss caudat putamen grey matter volum
loss striatal cortic white matter mccolgan et al clinician
spoken believ slow diseas progress rel control/baselin would
neurofila light chain nfl spoke research indic
nfl highli credibl easy-to-measur plasma biomark could
import endpoint clinic trial awar prospect longitudin
trial assess nfl level hd patient awar group work
valid endpoint chdi gener expert spoken believ
declin nfl could meaning may suggest reduc neuron damag
path market
believ qure capac manufactur suffici quantiti address
clinic commerci demand compani current stirred-tank product
leverag baculoviru insect-bas suspens system abil scale
need
confid qure like abl address hd preval opportun base
upon read-through biomarin manufactur process biomarin scale
baculoviru suspens system hemophilia gene therapi product believ
suffici produc enough product treat patient vg/kg dose rel
hemophilia gene therapi expect total dose hd smaller total
dose hd studi gc/brain gc/brain
roche/ioni wave life scienc clinic antisens oligonucleotid aso
treat diseas similar gene therapi approach agent bind htt
messeng rna therebi prevent translat mrna huntingtin protein
exact mechan silenc occur slightli differ two
approach microrna reli risc complex aso ionis/roch
broadli bind htt mrna wave program differenti select
target mutant htt mrna object preserv normal htt
ionis/roch program trial result plu compani recent
commentari suggest optim program roch regulatori plan includ meet
fda author consid acceler file base ole result
although see file base result like option
wave program trial initi result expect part initi
updat expect compani disclos safeti mhtt lower
multipl
 sma see opportun
gener see higher ceil hd gene therapi rel aso consist
ionis/roch enter clinic sever year ahead howev clinician
ask dont view program signific headwind qure
dose intrathec everi month depend result clinic trial addit
expert talk wonder aso abl treat motor manifest
diseas pk/pd studi found drug broadli distribut csf
outer brain may difficulti access striatum deep-brain
tissu associ sever chorea seen diseas longer term
expert specul us whether combin aso/gen therapi approach could
util gene therapi could address striatal associ issu aso could
address behavior issu believ associ damag cortex/out brain
multipl gene therapi announc variou stage preclin develop
program qure voyag closest clinic voyag expect file ind end
unlik qure program voyag program use plan directli dose
putamen thalamu vs qure plan dose putamen caudat nucleu
exact ramif differ unknown await addit data
program reassess respect program figur comparison
qure therapi vygr therapi see figur list hd competitor
asogen therapyadministrationintrathec spacedirect deep brain administrationadministr frequencychron sever time year lifeon timetargetal huntingtin mutant huntingtingener target huntingtin though theoret possibl design therapi target mutant huntingtinsafeti proceduralpotenti unknown chronic intrathec deliveryprocedur risk deep brain administrationsafeti therapytheoret advantag abl titrat dosepotenti risk therapi also lower normal huntingtinrisk off-target effectspotenti risk therapi also lower normal huntingtinrisk off-target effectshuntingtin loweringcan lower htt focu distributioncan lower htt focu distributionefficacylarg micrornather passeng strandtarget exon micrornather passeng strand optim increas ratio guid passeng strandsrout deliveryputamen caudateputamen thalamuspreclin efficacyresult dose-depend reduct mhtt reduct mhtt protein lower minipig dose gc/brain result htt mrna lower putamen lower caudat lower cortic neuron dose vgstatusind accept plan dose first patient late file ind late charl martineau pm univers toronto novemb
drug namepotenti diseas modifi deliverymoastatuscatalystslundbeckxenazinenoor inhibitorapprovedtevaaustedonoor inhibitorapprovedroche/ionishtt-asoyeschron intrathec spinal cordaso lower wt mutant result expect ole month data expect confer earli potenti updat regulatori path intrathec spinal cordaso select lower mutant result expect earli intrathec spinal cordaso select lower mutant result expect ye solutionan oxysterol-bas posit alloster modul nmda result expect deep braingen therapi lower wt mutant huntingtin enter dose first patient late deep braingen therapi lower wt mutant huntingtin preclinicalpotenti ind file ye molecul pre-mrna splice preclinicalplan nomin develop candid ye deep brainzinc finger transcript factor design select lower mutant huntingtin proteinpreclinicalsparkn/ayesmri-guid deep braingen therapi lower wt mutant nucleic charl martineau pm univers toronto novemb
huntington diseas primarili diseas afflict peopl european descent therefor
model europ model attribut base
probabl success
 price gross base price sma gene therapi
zolgensma price gross take account huntington
diseas preval sma
gene therapi preval market share reflect patient use
gene therapi long-term given potenti administr conveni rel
aso potenti better coverag deep brain
qure market share gt market europ reflect
gene therapi compani voyag sangamo also
product develop
cs revenu buildmartin ratehuntington diseas incid first initi diagnos preval ineligibile/no access preval entpeak shareyr peakgen therapi market uptak patient incidence- year entpeak shareyr peakgen therapi market uptak patient preval total- treat patient preval year- total gene therapi patient treat cy- qure market treat patients- gross ratehuntington diseas incid first initi diagnos preval ineligibile/no access preval entpeak shareyr peakgen therapi market uptak patient incidence- year entpeak shareyr peakgen therapi market uptak patient preval total- treat patient preval year- treat patient current year qure market cy treat patients- cumul treat patients- durabl yr patient pay perform net exus/europ japan turkey ratehuntington diseas incid first initi diagnos preval ineligibile/no access preval entpeak shareyr peakgen therapi market uptak patient incidence- year entpeak shareyr peakgen therapi market uptak patient preval total- treat patient preval year- treat patient current year qure market cy treat patients- cumul treat patients- durabl pay perform net charl martineau pm univers toronto novemb
hemophilia provid rariti
gene therapylik floor valu
potenti upsid
dose-confirm result hemophilia suggest compel
product profil improv conveni cost save current standard
care potenti differenti gene therapi develop
includ abil dose patient pre-exist anti-aav antibodi
trial current enrol patient top-lin result possibl
put compar timelin late-stag hemophilia
commerci split player estim attain
market share forecast achiev sale
potenti establish floor valuat po
qure develop padua-vari factor ix hyper-funct factor ix
variant gene therapi treatment hemophilia hemophilia monogen diseas
character impair clot abil potenti lead intern bleed damag
joint diseas fatal advanc therapeut option includ usag
prophylact therapi extend half-lif clot factor replac reduc risk
seriou complic life span hemophilia patient rel normal
develop countri howev patient qualiti life remain significantli impair
current standard care consist chronic infus rang everi
week factor ix life residu bleed risk remain
hemophilia x-link recess mean male gener diseas approxim
peopl global live diseas
potenti significantli improv qualiti life patient gene therapi
util capsid liver specif promot deliv function gene
patient singl dose may provid multi-year efficaci roughli normal
plasma level larg elimin spontan bleed risk need infus
demonstr compel initi product profil dose-confirm
studi three patient sever hemophilia enrol studi receiv singl
intraven infus vg/kg figur baselin characterist
week follow treatment mean level normal exceed threshold
associ elimin risk breakthrough bleed see uijl et al separ
expert mention comfort level like
elimin potenti risk micro bleed complic trauma surgeri etc
result remain strong compani report mean level week
patient respond level rang figur
detail patient requir infus report bleed event studi
one patient mild ast elev resolv without addit treatment
impact express patient trial requir steroid
figur impress activ week post-treat
compani present data isth juli
statusnegativeposit controlledposit controlledhep hep chep resolvedhep resolvedhep resolvedhemophilia statussever deficiencysever deficiencysever deficiencypre-screen treatmentprophylacticprophylacticprophylacticannu bleed rate prior antibodiesiggnegativenegativenegativeigmpositivenegativenegativeneutr antibodi activ charl martineau pm univers toronto novemb
derisk studi posit
acceler timelin qure commenc enrol hope-b trial june
prior dose patient dose-confirm studi given strong result
see trial high probabl success
hope-b trial multi-national multicent open-label single-arm studi expect enrol
adult moderate/sever hemophilia patient lead-in period
establish baselin bleed control patient treat
gc/kg primari endpoint level week secondari endpoint includ chang
annual bleed rate use week treatment compani measur
base one-stag chromogen assay
importantli trial test presenc pre-exist neutral antibodi
patient exclud trial trial dose first patient earli
februari qure announc achiev plan enrol earli
septemb suggest last patient dose set potenti
initi result would support acceler approv file
breakthrough therapi design prime design
allow amen develop path forward program potenti
acceler regular discuss regulatori author
see program larg de-risk padua-vari factor ix safe
success administ date patient qure competitor pfizer/spark
capsid safe deliv across multipl clinic studi higher dose
employ largest relev trial bmrn valrox trial
gc/kg dose data ultim requir address safety/immunogen
profil full highlight hope-b open-label trial news regard
good news degre adverse-ev perspect
durabl benefit unknown rational exist
expect long-term respons
long-term durabl liver-direct gene therapi unknown see reason expect
indefinit least long-term benefit understand durabl debat
import step back understand gene therapi work gene therapi either
integr case lentivirus-bas approach consid
non-integr case aav-deliv therapi latter approach aav
capsid deliv gene cell gene enter nucleu howev
integr dna cell instead form episom sinc gene
incorpor dna cell pass cell divides/repl
therefor natur turnov rate target tissu key determin
long-term durabl gene therapi
see multipl reason expect long-term durabl specif
nathwani hemophilia clinic studi evid year benefit
count util differ construct design differ
capsid differ gene variat nathwani academ studi human evid
first gener construct shown year durabl
human count succeed featur
similar construct upgrad factor ix gene cassett wild-typ
hyperfunct padua variant patient receiv vg/kg
studi continu see benefit mean activ year vs
activ first year patient remain free routin prophylaxi
competit smaller dataset vs may hold
spark/pfiz hemophilia gene therapi program also clinic
develop compar timelin qure program trial start enrol patient
run-in portion juli program demonstr
favor efficaci thu far patient express ten patient dose product
origin downstream process rang follow-up time
week week figur meanwhil level rang
first patient dose materi modifi manufactur process
week data patient disclos patient werent
week time level typic stabil therapi led reduct
bleed rate reduct factor use week follow-up
figur pfe/onc strong express patient
origin process materi
well toler patient grade relat
alt/ast elev three fifteen patient requir taper cours steroid
see sever potenti advantag rel spark program includ
could achiev broader label potenti treat larger
percentag popul qure trial exclud patient base
antibodi titer highlight patient number
screen-fail werent allow particip competitor gene therapi studi
contrast trial exclud patient high
antibodi titer capsid accord spark patient high antibodi
titer capsid potenti exclud treat
patent protect qure pfe/onc program use padua gene
variant qure claim ip cover use padua variant hemophilia
gene therapi suggest pfe/onc may infring patent
came market
potenti favor immunogen profil patient qure trial
requir steroid caution patient studi initi result
encourag patient trial requir steroid
sever hemophilia gene therapi program earlier develop
see signific nt threat sever year behind
appear offer potenti meaning differenti time
figur list hemophilia gene therapi develop
figur select hemophilia therapi develop lead
current standard care hemophilia patient involv util clot factor
replac product factor ix hemophilia patient treat either demand
subsequ traumatic/bleed event prophylact period infus frequent
time per week maintain minim factor level despit good efficaci safeti
achiev factor replac administr burden high cost therapi creat
unmet need longer-last therapi offer improv pharmacoeconom valu
cost factor replac therapi quit high therapi cost gross
per year adult patient treat prophylact ehl long-act factor product
 hemophilia patient inhibitor antibodi protein easili
consum factor drug cost account overal direct cost
hemophilia patient factor replac drug europ cost moder less per
year ohara et al estim discount factor replac
latam australia
substanti advanc made recent new extend half-lif ehl product
allow less frequent dose specif market-lead
product includ csl idelvion sanofi alprolix
manufacturerstatusnext eventmechan actionmethod administrationdos result expect inhibitorsubcutaneousonc monthlyconcizumabnovo studi antibodysubcutaneousdailygen result geneivon result late geneivon donesb-fixsangamomov gener constructn/afix gene gene edit ivon next dose cohort geneivon donest factor express rang patient low dose cohort week clinic geneivon donecb biopreclinicaln/afix geneivon charl martineau pm univers toronto novemb
anecdot report clinician spoken suggest despit develop
infrequ dose therapeut option effect cure much appeal patient
in-lin hemophilia patient survey feedback conduct earli believ
gene therapi repres potenti paradigm shift may provid function cure
bleed rate possibl reduc compar current achiev prophylact
factor use least one-tim infus lead long-term control moderate/sever
patient evid continu mount traction hemophilia gene therapi gain
strength market note enrol pace qure hope-b trial
encourag sign patient interest approach meanwhil believ gene therapi
may offer attract solut longer term patient emerg market
prophylaxi uptak low patient outcom tend favor
gt opportun emerg market may underestim
best standard care prophylact factor infus hemophilia offer patient
roughli normal life span significantli reduc disease-rel morbid compar
patient treat on-demand clot factor howev mani emerg market
usag prophylact therapi consider lower result cost complianc access
among factor wfh estim global hemophilia popul
receiv inadequ treatment
substanti variabl healthcar resourc avail patient region
market limit access healthcar provid factor replac product
high cost prophylaxi regimen despit potenti posit net save long run
anoth barrier optim manag
evidenc strong relationship higher overal gross nation incom gni
per capita factor unit util per patient
figur mean global fviii iu use per patient econom stratif
world feder hemophilia annual global survey publish octob credit suiss
lower-incom region also like util low-dos prophylaxi regimen
effect manag diseas
figur less effect low-dos prophylaxi often use emerg market
region frequent use low dose prophylaxi africa south-east asia
eastern mediterranean
world feder hemophilia annual global survey low dose prophylaxi wfh poster
clinician indic us patient emerg market wors outcom
compar develop market view support sever public subject
cross-sect studi pediatr moder sever hemophilia patient brazil
canada show canadian subject often treat prophylaxi
began treatment earlier age studi also demonstr fewer bleed better joint
health higher activ among canadian subject carneiro et al
studi found quality-of-lif score substanti lower china compar
report canadian european pediatr hemophilia subject tang et al
studi jamaica adult indic adult hemophilia signific joint
damag moder activ level low qualiti life score wharf et al
non-intervent studi emerg countri eastern europ north africa
middl east show subject joint recurr bleed target
joint baselin number increas subject year old gouider
iranian studi low-dos prophylaxi children sever hemophilia show
signific diseas burden baselin prior prophylaxi regimen mean annual bleed
rate mean hospit day on-demand
regimen eshghi peyman et al clinic appli thrombosis/ hemostasi
believ gene therapi could provid compel valu proposit region gene
therapi could provid best-in-class manag outcom patient addit
could provid net pharmacoeconom benefit given potenti reduc drug administr
bleed complic cost ex-u /europ countri util single-pay healthcar
system abl captur benefits/sav associ hemophilia
estim hemophilia patient live ex-u market pfizer/spark
natur well posit address market opportun given global footprint believ
qure compet build global infrastructur secur strateg partner
address opportun offer global opportun sourc valu creation
leverag strateg acquir latter point roch recent acquisit highlight
continu larg pharma interest hemophilia space well gene therapi broadli
prophylaxi regimen fxiii gni countrieshigh incomeupp incomelow incomelow iu/kgeveri per per charl martineau pm univers toronto novemb
credit suiss thought commerci adopt
believ first coupl post-launch year like demonstr cautiou
uptak sustain inflect like long-term lt safeti durabl profil evolv
favor believ ultim uptak may rel binari compar market
expect think lt durabl lt safeti comfort establish
year follow gene therapi launch market penetr rate could exceed
expect gene therapi becom wide accept treatment approach lt
durabl disappoint median effect year major lt safeti issu present
think uptak could disappoint greatli note year qure launch
patient dose old construct would year exposur data
clinic trial patient would approach year clinic data work
assumpt year post-launch entir hem popul
treat gene therapi repres approxim initi target
popul moderate/sever patient exclud base anti-aav antibodi prior
see demand direct patient interest well clinician wherea mani
clinician indic need conservat adopt new therapi refer patient
reluct switch effect therapi note uptak ehl product
fairli rapid hemophilia approach penetr hemophilia despit
moder conveni improv hem patient recent favor launch trajectori
hemlibra hemophilia provid anoth datapoint support patient accept new
improv modal
seen data human durabl factor
express year first gener construct
physician indic year durabl
would commerci viabl expect qure
year follow time
file
proven safe durabl gene therapi hemophilia
substanti uptak target
popul total
hemophilia popul qualifi mod-sever
therapi safe well toler
wouldnt major patient receiv treatment
ex-u ex- opportun substanti
sever addit benefit top direct
save factor replac product
bar gene therapi much higher
hemophilia compar sma dmd exampl
best avail product hemophilia allow
dose everi week less treatment burden
much lower past need
tri someth uncertain durabl safeti
long-term
uptak persist slow patient alway
wait next-gen product sinc re-dos still
theoret
patient take risk mani
lead small percentag integr could
meaning given high vector dose administ
transient liver toxic well understood
way product get approv less
year follow-up like hemophilia gene therapi
still readi prime-time
believ patient interest like go drive early-stag adopt recent consult
clinician anecdot notic even skeptic physician
report grow patient awar inbound question relat gene therapi
proprietari patient survey conduct earli also support interest gene therapi
high among adult patient caregiv pediatr patient believ
lead indic higher caution toward gene therapi clinician like abat
time absenc major advers event
hemophilia gene therapi bring save
system
annual cost routin prophylaxi usual target trough factor level
substanti rang potenti gross price per adult patient assum
annual price gross-to-net discount includ complianc discount
rate lifetim factor replac cost adult prophylaxi regimen
greater without account indirect cost
believ annual subscription-bas pay-for-perform reimburs system would
enabl compani fairli accur captur valu hemophilia gene therapi
rel lump-sum payment believ qure hemophilia gene therapi
develop activ engag optim valu product sharehold
patient current model one-tim lump-sum payment net
roughli equival year npv factor-bas therapi given low visibl
implement annual payment model single-pay countri essenti everyth
ex-u model annual payment roughli pariti price local cost prophylact
factor replac therapi net /row
one signific unknown around hemophilia gene therapi durabl effect
consult gener indic durabl efficaci last year median basi
would univers appeal clinicians/pati ultim abil eas
re-dos patient like influenc debat current data support
sustain efficaci year human continu think median efficaci
reason still unproven expect time
model attribut base follow assumpt
probabl success
gene therapi market penetr target market
qure market share europ base assumpt driven
qure compar timelin pfe/onc promis initi efficaci
long-term potenti clinic differenti base potenti broader
address popul immunolog profil expect adjust share
assumpt up/down competit profil develop
us gene neutral aav therapi expect launch market penetr primari market pt therapi treat therapi treat patient treat gene treat gene therapi treat per patient charl martineau pm univers toronto novemb
sever sourc pipelin option
support qure manufactur
hem gene therapi ind expect trail competitor
program therapi util novel approach current hem gene therapi
clinic profil leav room improv
fabri gene therapi could interest program trail
competitor fabri gene therapi clinic addit posit result
miqur technolog increas interest compani
program
qure built-out manufactur capabl valuabl stand-alone basi
augment long-term thesi around name potenti enabl faster
develop timelin pipelin product
hemophilia potenti upsid
similar hemophilia hemophilia character impair clot abil potenti
lead intern bleed damag joint differ two diseas
hemophilia result insuffici factor viii protein hemophilia result
insuffici factor ix protein hemophilia fatal advanc therapeut option
reduc risk seriou complic life span rel normal
develop countri howev qualiti life remain significantli impair current
standard care consist chronic infus rang weekli
miss protein factor viii fviii life multipl group develop gene therapi
hemophilia figur detail approxim peopl
global live hemophilia
figur select hemophilia product stand
namemoastatuscommentsbiomarinvalroxgen file acceler approv list run-in portion trial assess baselin characterist data look encourag start enrol patient lead-in trial octob patient dose start factor data suggest dose weekli potenti less start novemb per clincaltri gov seen clinic data start januari per clincaltri gov seen clinic data start march per clincaltri gov seen clinic data therapypreclinicalind file therapypreclinicalexpect enter ind enabl studi soonasc therapypreclinicalcurr toxicolog studiessanofiundisclosedgen therapypreclinicallentiviru approach statu -tbabluebird/novo nordiskundisclosedgen editingpreclinicalannounc collabor agreement develop therapi hemophilia charl martineau pm univers toronto novemb
preclin develop hemophilia unlik hemophilia gene
therapi follow provid patient truncat factor viii gene provid
patient modifi gene produc highli activ protein abl
activ clot cascad specif factor independ fviii sever potenti
advantag approach includ
potenti lower risk hepatocyt burn current hemophilia gene
therapi program deliv fviii gene hepatocyt goal turn
cell fviii factori howev fviii natur made hepatocyt
could lead stress cell figur detail contrast
natur produc hepatocyt
neutral fviii inhibitor antibodi fviii protein
sinc encod modifi gene abl bypass
potenti fviii inhibitor expand potenti util broader
section moderate/sever hemophilia patient
milanov et al detail mous studi independ group
provid background approach
figur high dose fviii mice associ liver cell stress
compani report tunicamycin drug known caus liver cell stress
ex vivo studi variant specif variant encod led
meaning thrombin product potenti better current approv bypass agent
figur detail separ hemophil mice fviii -/- mice treatment
led dose-depend increas fviii mimet activ figur lastli gc/kg
dose associ meaning hfix protein expect translat
therapeut relev fviii mimet activ human
figur show fviii mimet activ fviii
figur dose-depend increas fviii mimet activ
hemophil mice
super mid gc/kg low gc/kg
qure plan file ind set commenc first clinic
studi initi clinic data potenti becom avail
opportun competit field
fabri anoth x-link inherit lysosom storag disord result insuffici
product enzym due mutat gene call gla without proper
gla-direct enzym product accumul substanc call globotriaosylceramid
occur lead damag across multipl organ includ kidney
cardiovascular nervou system
current standard care enzym replac therapi agalsidase-beta -alfa
two current approv therapi sanofi fabrazym takeda replag avail
ex-u therapi provid benefit limit abil target
heart infus enzym highli immunogen therapi cost per year
gener combin annual sale
gene therapi encod modifi naga gene naga code product
enzym therapeut -gal activ similar gla gene reduc level
significantli lower risk immunogen nativ gla qure therapeut hypothesi
support mice studi found inject modifi naga gene therapi led
superior gla activ liver kidney heart compar replag fabrazym
figur detail likewis qure studi found led increas
gla activ reduc level fabri mice
figur inject modifi naga superior efficaci fabrazym replag
preclin develop trail sever gene therapi competitor
develop figur detail ultim clinic profil vs
competitor dictat potenti market opportun drug
vivo lentiviru approach gla genehav disclos earli data gene therapi encod human glajust enter gene therapi encod glajust enter clinicamicuspreclinicaln/auniqurepreclinicalgen therapi encod charl martineau pm univers toronto novemb
built-out manufactur process pay dividend
product brought clinic
manufactur key focu fda evid efficaci gene therapi
commerci scale human often gate step approv srpt microdystrophin
program novarti zolgensma believ qure well-posit front
compani current stirred-tank product leverag baculoviru insect-bas
suspens system space scale need massachusett
facil capabl enabl compani pursu aggress clinic develop
timelin carv rapid path market gene therapi asset
scale-up delay truncat elimin initi clinic test
studi typic conduct commercial-scal product
difficult assign direct valu qure built-out in-hous manufactur process
think capabl differenti qure sever peer development-stag gene
therapi elev compani attract potenti acquisit target sinc
qure pipelin potenti scale readi manufactur avail support
multipl clinic and/or commerci program parallel effect asset support
higher floor valu rais ceil qure
arriv target price use blend valuat approach
product-bas dcf dcf
dcf model use discount rate in-lin standard discount rate appli
late-stag develop compani fulli dilut share million long-term oper
margin tax rate assign per share pipelin valu account
platform valu potenti hemophilia fabri diseas sca type
opportun reflect increment sale pipelin project
detail dcf compon includ follow
 a-bas valuat scenario support target reflect
reduct sg increas revenu
assign weight dcf think qure substanti
 potenti evidenc recent gene therapi acquisit nite
high interest hemophilia space bivv potenti multi-billion
dollar opportun huntington diseas
probabl success
standard probability-ofsuccess po assumpt phase asset
phase asset phase asset asset nda/bla stage
slight adjust base histor probabl success specif diseas categori
standard mind assign follow probabl success qure pipelin
hemophilia slightli standard po asset
reflect strong durabl strong data partial
off-set limit patient follow-up small sampl size
huntington diseas slightli standard po
asset enter clinic studi reflect strong preclin mechanist
rational off-set one first mirna gene therapi clinic develop
equival
compani cash cash equival end septemb
project net cash use oper
blue sky scenario reflect posit earli result result
increas probabl success correspond increas
platform valu grey sky scenario reflect failur reduct
regulatory/clin risk includ limit trial enrol delay poorli design
studi inadequ endpoint enough power neg safety/efficaci signal
neg dsmb/health author rule specif
emerg safeti issu studi
lack efficaci wane durabl studi
develop risk associ includ lack efficaci
occurr safety/toler issu due procedur therapi
liquidity/fund difficulti develop candid
manufacturing/suppli risk includ limit suppli disrupt product batch
adher qualiti standard manufactur shutdown due contamin technic
difficulti produc function complex molecul delay construction/certif
lack materi compar among
inadequ
manufactur gene therapi challeng scale-up process also
challeng inabl produc consist high-qual batch meet applic
requir could result signific delay program
inabl manufactur enough product meet commerci demand
gene therapi manufactur build-out expens could requir addit
commerci risk includ limit lower-than-expect adopt drug
target popul competit clinical/exist agent payer-impos access restrict
access reimburs issu product gene therapi new
unclear
market
pay-for-perform lump-sum payment
competit pressur may face competit new ehl prophylaxi
therapi like idelvion gene therapi pfe/onc
pend data unclear degre differenti
may abl suffici differenti
ionis/roch aso therapi treatment huntington diseas
expect get market first sever gene therapi develop
could pose risk includ voyag program competit threat
hemophilia fabri program
price challeng given gene therapi like requir potenti larg up-front
payment unit state
incom statementfisc year end decemb million except per share develop gener administr incom loss tax benefit profit averag share weight averag share ep charl martineau pm univers toronto novemb
figur qure balanc sheet
uniqurebal sheet million except per share asset cash expens current current equip stockhold equitycurr liabil account term current term conting prefer units/convert prefer equitycommon paid-in stockhold liabil stockhold million except per share activ net incom compens debt dispos fix asset liabil expens cash use oper activ purchas properti invest cash use invest activ proce issuanc exercis stock issuanc prefer stock net issuanc issuanc common stock cash use financ currenc decreas increas cash cash restrict cash begin restrict cash end restrict end charl martineau pm univers toronto novemb
compani mention price
